Pharmaceuticals company Mankind Pharma announced Q3FY26 results Revenue: Rs 3,567 crore against Rs 3,199 crore during Q3FY25, change 12%. EBITDA: Rs 816 crore against Rs 819 crore during Q3FY25, change 0%. EBITDA Margin: 22.9% for Q3FY26. PAT: Rs 414 crore against Rs 378 crore during Q3FY25, change 10%. PAT Margin: 11.6% for Q3FY26. Diluted EPS of Rs 9.9 up by 6.7% YoY (FV Re.1). Rajeev Juneja, Vice Chairman & Managing Director, said: “Mankind’s revenue increased 11.5% YoY, with adj. EBITDA margins of 25.9%, primarily due to improvement in domestic pharma and BSV consolidation. Mankind’s chronic share increased by 200 bps YoY to 39.3%, driven by strong growth of 16.7% in cardiac and 14.4% in anti-diabetes. Revenue from OTC grew by 5.2% in Q3FY26 vs -2.6% in Q2FY26. We expect growth to improve further. BSV growth initiatives progressing well; Strong double-digit growth in Q3. We remain confident of delivering long term sustainable growth anchored by four key pillars - steady base business, fast-growing specialty chronic, high-potential OTC business, and super specialty BSV portfolio.” Result PDF